| abstract |
REFERS TO COMPOUNDS DERIVED FROM THIAZOLO [4,5-D] PYRIMIDIN-2 (3H) -ONE OF FORMULA (I) WHERE R1 IS CH3 OR C2H5; R2 AND R3 ARE EACH H OR CH3; R4, R5, R6, AND R7 ARE EACH H, CH3, OR C2H5. PREFERRED COMPOUNDS ARE: 7 - [(R) -1-HYDROXY-4-METHYLPENTAN-2-ILAMINE] -5- [1- (PYRIDIN-2-IL) ETHYLTIO] THIAZOLO [4,5-d] PYRIMIDIN-2 ( 3H) -ONE, 7 - [(R) -1-HYDROXY-4-METHYLPENTAN-2-ILAMINE] -5- [1- (2,4-DIMETHYLPYRIDIN-2-IL) ETHYLTIO] THIAZOLO [4,5-d ] PYRIMIDIN-2 (3H) -ONE, 7 - [(R) -1-HYDROXY-4-METHYLPENTAN-2-ILAMINO] -5- [1- (2-METHYLPYRIDIN-2-IL) ETHYLTIO] THIAZOLO [4, 5-d] PYRIMIDIN-2 (3H) -ONE, 7 - [(R) -1-HYDROXY-4-METHYLPENTAN-2-ILAMINO] -5- [1- (3-METHYLPYRIDIN-2-IL) ETHYLTIO] THIAZOLE [4,5-d] PYRIMIDIN-2 (3H) -ONE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SAID COMPOUNDS ARE ANTAGONISTS OF THE CX3CR1 RECEPTOR, BEING USEFUL IN THE TREATMENT OF CEREBROVASCULAR ACCIDENT OR TRANSITORY BRAIN INJURY (TBI) |